Grifols (GRFS) Net Income towards Common Stockholders (2010 - 2020)
Grifols (GRFS) reported Net Income towards Common Stockholders of $330.1 million for Q1 2020, up 69.41% on a YoY basis from $194.8 million in Q2 2019, and down 55.46% quarter-over-quarter from $741.2 million in Q4 2019.
Grifols (GRFS) Net Income towards Common Stockholders (2010 - 2020) Analysis & Trends
Grifols has reported Net Income towards Common Stockholders for 10 years, with the latest figure at $330.1 million in Q1 2020.
- For the quarter ending Q1 2020, Net Income towards Common Stockholders rose 69.41% year-over-year to $330.1 million; the trailing twelve-month figure through Dec 2021 stood at $330.1 million (down 69.19% YoY), and the FY2025 full-year result was $467.9 million, up 178.92% from the prior year.
- Net Income towards Common Stockholders for Q1 2020 stood at $330.1 million, down from $741.2 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $882.3 million in Q4 2017, with the low at $150.5 million in Q4 2016.
- Historically, Net Income towards Common Stockholders has averaged $389.3 million across 5 years, with a median of $264.1 million in 2018.
- Annual changes were most pronounced in 2016 — Net Income towards Common Stockholders soared 137874.31% — and 2019, when it retreated 26.23%.
- Grifols' Net Income towards Common Stockholders stood at $150.5 million in 2016, then surged by 486.37% to $882.3 million in 2017, then declined by 9.06% to $802.4 million in 2018, then fell by 7.63% to $741.2 million in 2019, then slumped by 55.46% to $330.1 million in 2020.
- The last three Net Income towards Common Stockholders figures came in at $330.1 million (Q1 2020), $741.2 million (Q4 2019), and $194.8 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.34 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 330.09 Mn |
| Dec 31, 2019 | 741.18 Mn |
| Mar 31, 2019 | 194.84 Mn |
| Dec 31, 2018 | 802.38 Mn |
| Jun 30, 2018 | 209.54 Mn |
| Mar 31, 2018 | 264.14 Mn |
| Dec 31, 2017 | 882.31 Mn |
| Jun 30, 2017 | 255.10 Mn |
| Mar 31, 2017 | 247.88 Mn |
| Dec 31, 2016 | 150.47 Mn |
| Sep 30, 2016 | 453.28 Mn |
| Jun 30, 2016 | 202.82 Mn |
| Mar 31, 2016 | 327.20 Mn |
| Dec 31, 2015 | 143.08 Mn |
| Sep 30, 2015 | 155.84 Mn |
| Jun 30, 2015 | 147,000.37 |
| Mar 31, 2015 | 145.17 Mn |
| Sep 30, 2013 | 111.62 Mn |
| Jun 30, 2013 | 119.87 Mn |
| Mar 31, 2013 | 120.15 Mn |